CorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day Live Webcast Today

CorMedix Inc. Provides Comprehensive Pipeline Update

During Research and Development Day

Live Webcast Today, July 12, 2017, beginning at 8:30am

Bedminster, NJ July 12, 2017 CorMedix Inc.

(NYSE MKT: CRMD), a biopharmaceutical company focused on developing

and commercializing therapeutic products for the prevention and

treatment of infectious and inflammatory disease, today provided a

comprehensive overview and update on its ongoing pre-clinical and

clinical development programs, based on its taurolidine technology

platform. The R&D Day event will be webcast live

and archived on CorMedix's website. To access the

webcast, visit the Events page at www.cormedix.com/media-publications/events/.

speakers include Prabir Roy-Chaudhury, MD, Ph.D., Co-Principal

Investigator of the Neutrolin Phase 3 LOCK-IT

100 clinical trial, Director of the Division of Nephrology and the

Arizona Kidney and Vascular Center at University of Arizona, and

Co-chair of the American Society for Nephrology's Kidney

Health Initiative; Allison O'Neill, M.D., Assistant Professor

of Pediatrics at Harvard Medical School and Research Fellow at the

Dana-Farber Cancer Institute; Z. Paul Lorenc, M.D., F.A.C.S.,

World-renowned, board-certified Aesthetic Plastic Surgeon; and

Gregory Schultz, Ph.D., Director of the Institute for Wound

Research and Professor of Obstetrics and Gynecology at the

University of Florida.

has advanced several preclinical R&D programs, building upon

the key characteristics of taurolidine. These include potent

anti-microbial activity without resistance, anti-inflammatory

properties mediated by a reduction in certain cytokines including

IL-1, IL-6 and TNF, as well as selective pro-apoptotic and

cytotoxic activity against cancer cells. Taurolidine is also known

to penetrate biofilms and retain its activity against highly

drug-resistant bacteria and fungi, making it a potentially valuable

molecule for addressing the unmet need for new anti-microbial

R&D Day event focuses on three key areas of CorMedix's

taurolidine-based pipeline:

medical devices that incorporate taurolidine

taurolidine-based therapy for cancer

development of Neutrolin for the

prevention of bloodstream infections

Development of Medical Devices that Incorporate

has focused its R&D efforts to three initial medical device

areas where taurolidine incorporation may add value and potentially

improve patient outcomes. These include:

Development of anti-microbial suture

materials to prevent surgical site infections

Development of antimicrobial

hydrogels to help prevent infections in burns and other wounds as well as treat

infections in those sites. The hydrogels may also be effective as

treatments for diabetic foot ulcers.

Development of non-woven antimicrobial

meshes to prevent infection and graft failure following

hernia repair and reconstructive surgery

2018 U.S. market is projected to be $1.7 billion for sutures, and

$1.0 billion each for hydrogels and non-woven meshes.

Development of Anti-Microbial Suture materials

successful in integrating multiple concentrations of taurolidine

(2%-10%) into monofilament suture materials, where the taurolidine

is dispersed throughout the matrix of the fibers (one prepared with

a homopolymer of epsilon-caprolactone and another fiber composed of

rho-dioxanone). Taurolidine could also be loaded onto the surface

of multifilament suture materials by integrating the drug into the

taurolidine-incorporated sutures were tested against clinically

significant bacterial species, including methicillin-resistant

Staphylococcus aureus

(MRSA), Staphylococcus

epidermidis, and Pseudomonas aeruginosa using two different

Effectiveness of the materials at eradicating these potentially

deadly microbes was confirmed using zone of inhibition (ZOI), where

bacterial growth was completely inhibited in the vicinity of the

taurolidine-loaded fibers; and by direct bacteria killing assays

that showed ~10 log (>99.9%) reduction in bacteria following

incubation with 6% taurolidine sutures.

process of testing large-scale manufacturing of polydioxanone

sutures containing 7% taurolidine that mimics the processes in use

today. It involves creating drug-loaded polymer pellets that can be

extruded in a line that enables annealing and drawing similar to

the current commercial manufacturing of sutures. Zone of inhibition

studies recently confirmed that the taurolidine sutures retain

their antimicrobial activity when manufactured by this scalable

Development of Anti-Microbial Non-Woven Meshes

non-woven mesh candidates were prepared by electrospinning using a

variety of commercially available resorbable polymer constructs and

loaded with taurolidine at strengths ranging from 21-59% by weight.

The meshes were submerged in suspended cultures of P. aeruginosa and MRSA.

Taurolidine-incorporated meshes demonstrated complete killing of

these deadly bacteria at all strengths tested in less than four

Development of Anti-Microbial Hydrogels

(HA) hydrogels containing taurolidine demonstrated complete killing

of suspended cultures of P.

aeruginosa and MRSA at all concentrations of Taurolidine

tested (1.5%-6%). Furthermore, taurolidine hydrogels were effective

at penetrating mature biofilms of P. aeruginosa on the surface of pig

skin explants. High molecular weight HA + 3% taurolidine and

myristic acid (penetration enhancer) also showed complete killing

of the biofilm bacteria.

is currently conducting proof-of-concept studies in animal models

for each of its medical device candidates, and these studies will

continue during the second half of 2017.

regulatory strategy for its taurolidine-incorporated medical

devices is to utilize the 510(k) pathway, which uses predicate